Kenvue Inc. (NYSE:KVUE) to Issue Quarterly Dividend of $0.21

by · The Cerbat Gem

Kenvue Inc. (NYSE:KVUE – Get Free Report) declared a quarterly dividend on Thursday, October 17th,RTT News reports. Shareholders of record on Wednesday, November 13th will be given a dividend of 0.205 per share on Wednesday, November 27th. This represents a $0.82 dividend on an annualized basis and a yield of 3.45%. The ex-dividend date of this dividend is Wednesday, November 13th.

Kenvue has a dividend payout ratio of 67.2% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Kenvue to earn $1.22 per share next year, which means the company should continue to be able to cover its $0.82 annual dividend with an expected future payout ratio of 67.2%.

Kenvue Stock Up 0.4 %

Shares of Kenvue stock opened at $23.78 on Tuesday. The firm’s 50 day moving average price is $22.65 and its 200-day moving average price is $20.55. The company has a quick ratio of 0.68, a current ratio of 0.99 and a debt-to-equity ratio of 0.69. Kenvue has a 52-week low of $17.67 and a 52-week high of $23.88. The company has a market cap of $45.54 billion, a P/E ratio of 43.27, a PEG ratio of 3.10 and a beta of 1.36.

Kenvue (NYSE:KVUE – Get Free Report) last released its earnings results on Thursday, November 7th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. The company had revenue of $3.90 billion during the quarter, compared to analysts’ expectations of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.41%. Kenvue’s revenue for the quarter was down .4% on a year-over-year basis. During the same period last year, the business earned $0.31 EPS. On average, sell-side analysts predict that Kenvue will post 1.07 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on KVUE shares. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Royal Bank of Canada lowered shares of Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price target for the company. in a report on Tuesday, September 24th. Piper Sandler boosted their price target on shares of Kenvue from $20.00 to $21.00 and gave the stock a “neutral” rating in a report on Monday, September 23rd. Jefferies Financial Group assumed coverage on shares of Kenvue in a report on Tuesday, September 24th. They issued a “buy” rating and a $27.00 price target for the company. Finally, JPMorgan Chase & Co. boosted their price target on shares of Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $22.64.

Read Our Latest Stock Analysis on KVUE

About Kenvue

(Get Free Report)

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

Further Reading